Revance Therapeutics Inc [RVNC] stock is trading at $2.42, down -5.84%. An important factor to consider is whether the stock is rising or falling in short-term value. The RVNC shares have gain 2.98% over the last week, with a monthly amount drifted -14.79%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Revance Therapeutics Inc [NASDAQ: RVNC] stock has seen the most recent analyst activity on January 29, 2024, when Mizuho downgraded its rating to a Neutral and also revised its price target to $9 from $16. Previously, Goldman downgraded its rating to Neutral on January 09, 2024, and dropped its price target to $8. On August 16, 2023, upgrade upgraded it’s rating to Neutral but maintained its price target of $20 on the stock. Morgan Stanley started tracking the stock assigning a Equal-Weight rating and suggested a price target of $27 on October 11, 2022. Goldman initiated its recommendation with a Buy and recommended $33 as its price target on September 22, 2022. Wells Fargo downgraded its rating to Equal Weight for this stock on October 25, 2021, and downed its price target to $17. In a note dated October 15, 2020, Needham reiterated an Buy rating on this stock and boosted its target price from $36 to $42.
Revance Therapeutics Inc [RVNC] stock has fluctuated between $2.30 and $25.33 over the past year. Currently, Wall Street analysts expect the stock to reach $21 within the next 12 months. Revance Therapeutics Inc [NASDAQ: RVNC] shares were valued at $2.42 at the most recent close of the market. An investor can expect a potential return of 767.77% based on the average RVNC price forecast.
Analyzing the RVNC fundamentals
Revance Therapeutics Inc [NASDAQ:RVNC] reported sales of 236.65M for the trailing twelve months, which represents a growth of 5.28%. Gross Profit Margin for this corporation currently stands at 0.68% with Operating Profit Margin at -1.28%, Pretax Profit Margin comes in at -1.32%, and Net Profit Margin reading is -1.34%. To continue investigating profitability, this company’s Return on Assets is posted at -0.62, Equity is 3.85 and Total Capital is -0.69. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-4.43.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 2.35 points at the first support level, and at 2.27 for the second support level. However, for the 1st resistance point, the stock is sitting at 2.54, and for the 2nd resistance point, it is at 2.66.
Ratios To Look Out For
For context, Revance Therapeutics Inc’s Current Ratio is 5.37. On the other hand, the Quick Ratio is 4.64, and the Cash Ratio is 1.93. Considering the valuation of this stock, the price to sales ratio is 1.07.
Transactions by insiders
Recent insider trading involved Jordan Erica, Chief Commercial Officer, that happened on Apr 16 ’24 when 2392.0 shares were sold. CFO, Schilke Tobin completed a deal on Mar 18 ’24 to sell 9361.0 shares. Meanwhile, President Sjuts Dustin S sold 9211.0 shares on Mar 18 ’24.
